Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2265 PWToday Stories

EMBL Ventures portfolio company Luxendo acquired by Bruker

09 May 17

EMBL Ventures today announced that it has sold its portfolio company Luxendo to Bruker (NASDAQ: BRKR). EMBL Ventures was lead investor with LSP in October 2015 when Luxendo was created as a spin-off by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM).

Luxendo develops light-sheet microscopes for life science research using the proprietary Single Plane Illumination Microscopy (SPIM) technique developed at EMBL. The technology allows scientists to observe living organisms for extended periods of time without them being adversely impacted by photo-toxicity by illuminating sequentially a stack of small slices of the organism that is actively being viewed. Luxendo launched its first two products, the MuVi-SPIM and InVi-SPIM microscopes, in 2016. Luxendo is based in Heidelberg, Germany.

Stefan Herr, Managing Director at EMBL Ventures, said, “We are delighted to have supported Luxendo and its management team from its creation through its development to the important corporate milestone that we have announced today. We have worked closely with the Company to identify this market opportunity and to implement its successful commercialization strategy. We are confident that Bruker will support Luxendo in the next phase of its development, making this exciting and innovative technology available to a growing number of life science researchers around the globe.”

Jürgen Bauer, Deputy Managing Director at EMBLEM, said, “The acquisition of Luxendo by Bruker, just 1.5 years after the Company’s creation, will allow the rapid deployment of EMBL’s proprietary SPIM technology to users worldwide and will provide a strong platform to support Luxendo’s sustained growth. Luxendo’s rapid success would not have been possible without the excellent collaboration within EMBL’s unique technology transfer and innovation ecosystem, which benefits from the great teamwork and enthusiasm of the EMBL scientists and the experienced managers from EMBL Ventures and EMBLEM.”

Andreas Pfuhl, CEO of Luxendo, commented, “Light-sheet microscopy is revolutionizing bio-imaging, and Luxendo, with its SPIM technology, has a highly influential role in the adoption of this type of imaging in an ever-growing variety of live-sample studies. EMBL Ventures and EMBLEM have been instrumental to the development of our business and this exit. We are thrilled to be joining Bruker, an internationally esteemed instrumentation company whose philosophy, culture and vision are so closely aligned with ours.”

“It has been very rewarding to witness the rapid trajectory from pioneering technology developed at EMBL to Luxendo’s well-designed, robust microscopes, and now this acquisition,” said EMBL Director General Iain Mattaj. “We anticipate that Bruker, with its excellent reputation in providing innovative techn

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.